PT  - JOURNAL ARTICLE
AU  - Saliani, Mahsa
AU  - Jalal, Razieh
AU  - Ahmadian, Mohammad Reza
TI  - From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
AID  - 10.20892/j.issn.2095-3941.2018.0530
DP  - 2019 Aug 01
TA  - Cancer Biology and Medicine
PG  - 435--461
VI  - 16
IP  - 3
4099  - http://www.cancerbiomed.org/content/16/3/435.short
4100  - http://www.cancerbiomed.org/content/16/3/435.full
SO  - Cancer Biol Med2019 Aug 01; 16
AB  - Among the numerous oncogenes involved in human cancers, KRAS represents the most studied and best characterized cancer-related genes. Several therapeutic strategies targeting oncogenic KRAS (KRASonc) signaling pathways have been suggested, including the inhibition of synthetic lethal interactions, direct inhibition of KRASonc itself, blockade of downstream KRASonc effectors, prevention of post-translational KRASonc modifications, inhibition of the induced stem cell-like program, targeting of metabolic peculiarities, stimulation of the immune system, inhibition of inflammation, blockade of upstream signaling pathways, targeted RNA replacement, and oncogene-induced senescence. Despite intensive and continuous efforts, KRASonc remains an elusive target for cancer therapy. To highlight the progress to date, this review covers a collection of studies on therapeutic strategies for KRAS published from 1995 to date. An overview of the path of progress from earlier to more recent insights highlight novel opportunities for clinical development towards KRASonc-signaling targeted therapeutics.